Probing the structures of leishmanial farnesyl pyrophosphate synthases: Homology modeling and docking studies

Journal of Chemical Information and Modeling

Volumn 48, Issue 5, 2008, Pages 1026-1040

  Mukherjee, Prasenjit ^a   Desai, Prashant V ^a,c   Srivastava, Anuradha ^a   Tekwani, Babu L ^a   Avery, Mitchell A ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; MECHANICS; MOLECULAR MODELING; QUANTUM THEORY;

ANTILEISHMANIAL THERAPY; FARNESYL PYROPHOSPHATES; LEISHMANIA DONOVANI; POTENTIAL TARGETS; QUANTUM MECHANICS/MOLECULAR MECHANICS; RATIONAL DRUG DESIGNS; SITE DIRECTED MUTAGENESIS; VIRTUAL SCREENING;

LIGANDS;

GERANYLTRANSFERASE; LIGAND; PYROPHOSPHATE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; LEISHMANIA; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN CONFORMATION; REPRODUCIBILITY; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; DIPHOSPHATES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GERANYLTRANSTRANSFERASE; HUMANS; LEISHMANIA; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; REPRODUCIBILITY OF RESULTS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 45749158183     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci700355z     Document Type: Article

References (73)

1. Desjeux, P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 2001, 95 (3), 239-243.
2. Bora, D. Epidemiology of visceral leishmaniasis in India. Natl. Med. J. India 1999, 12 (2), 62-68.
3. World Health Organization: Magnitude of the Problem, http://www.who.int/ leishmaniasis/burden/magnitude/burden_magnitude/en/index.html (accessed Feb 2008).
4. Croft, S. L.; Yardley, V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 2002, 8 (4), 319-342.
5. Roberts, W. L.; McMurray, W. J.; Rainey, P. M. Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrob. Agents Chemother. 1998, 42 (5), 1076-1082.
6. Grogl, M.; Thomason, T. N.; Franke, E. D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 1992, 47 (1), 117-126.
7. Adler-Moore, J.; Proffitt, R. T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 2002, 49 (Suppl 1), 21-30.
8. Escobar, P.; Yardley, V.; Croft, S. L. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient seid mice. Antimicrob. Agents Chemother. 2001, 45 (6), 1872-1875.
9. Alrajhi, A. A.; Ibrahim, E. A.; De Vol, E. B.; Khairat, M.; Faris, R. M.; Maguire, J. H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N. Engl. J. Med. 2002, 346 (12), 891-895.
10. Geusens, P.; McClung, M. Review of risedronate in the treatment of osteoporosis. Expert Opin. Pharmacother. 2001, 2 (12), 2011-2025.
11. Pistevou-Gombaki, R.; Eleftheriadis, N.; Sofroniadis, I.; Makris, P.; Rouloulias, V. Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium Pamidronate. J. Exp. Clin. Cancer Res. 2002, 21 (3), 429-432.
12. ( 12) Delmas, P. D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359 (9322), 2018-2026.
13. Coleman, R. E. Bisphosphonates: clinical experience. Oncologist 2004, 9 (Suppl. 4), 14-27.
14. Berenson, J. R. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin. Oncol. 2002, 29 (6 Suppl. 21), 12-18.
15. Langston, A. L.; Ralston, S. H. Management of Paget's disease of bone. Rheumatology (Oxford) 2004, 43 (8), 955-959.
16. van Beek, E.; Pieterman, E.; Cohen, L.; Lowik, C.; Papapoulos, S. Farnesyl pyrophosphate synthase is the molecular target of nitrogencontaining bisphosphonates. Biochem. Biophys. Res. Commun. 1999, 264 (1), 108-111.
17. Bergstrom, J. D.; Bostedor, R. G.; Masarachia, P. J.; Reszka, A. A.; Rodan, G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 2000, 373 (1), 231-241.
18. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296 (2), 235-242.
19. Fisher, J. E.; Rodan, G. A.; Reszka, A. A. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141 (12), 4793-4796.
20. Rogers, M. J.; Gordon, S.; Benford, H. L.; Coxon, F. P.; Luckman, S. P.; Monkkonen, J.; Frith, J. C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88 (12 Suppl.), 2961-2978.
21. Yardley, V.; Khan, A. A.; Martin, M. B.; Slifer, T. R.; Araujo, F. G.; Moreno, S. N.; Docampo, R.; Croft, S. L.; Oldfield, E. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother. 2002, 46 (3), 929-931.
22. Rodriguez, N.; Bailey, B. N.; Martin, M. B.; Oldfield, E.; Urbina, J. A.; Docampo, R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate Pamidronate. J. Infect. Dis. 2002, 186 (1), 138-140.
23. Cornforth, J. W.; Comforth, R. H.; Popjak, G.; Yengoyan, L. Studies on the biosynthesis of cholesterol. XX. Steric course of decarboxylation of 5-pyrophosphomevalonate and of the carbon to carbon bond formation in the biosynthesis of farnesyl pyrophosphate. J. Biol. Chem. 1966, 241 (17), 3970-3987.
24. Patny, A.; Desai, P. V.; Avery, M. A. Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding. Proteins 2006, 65 (4), 824-842.
25. Sabnis, Y.; Rosenthal, P. J.; Desai, P.; Avery, M. A. Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors. J. Biomol. Struct. Dyn. 2002, 19 (5), 765-774.
26. Sabnis, Y. A.; Desai, P. V.; Rosenthal, P. J.; Avery, M. A. Probing the structure of falcipain-3, a cysteine protease from Plasmodium falciparum: comparative protein modeling and docking studies. Protein Sci. 2003, 12 (3), 501-509.
27. Singh, N.; Cheve, G.; Avery, M. A.; McCurdy, C. R. Comparative protein modeling of 1-deoxy-D-xylulose-5-phosphate reductoisomerase enzyme from Plasmodium falciparum: a potential target for antimalarial drug discovery. J. Chem. Inf. Model. 2006, 46 (3), 1360-1370.
28. EBI Toolset: ClustalW2. http://www.ebi.ac.uk/clustalw (accessed Feb 2008).
29. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234 (3), 779-815.
30. RCSB Validation Server (V11.1A), http://deposit.pdb.org/validate (accessed Feb 2008).
31. Luthy, R.; Bowie, J. U.; Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature 1992, 356 (6364), 83-85.
32. Godzik, A.; Kolinski, A.; Skolnick, J. Topology fingerprint approach to the inverse protein folding problem. J. Mol. Biol. 1992, 227 (1), 227-238.
33. Philipp, D. M. F.; Richard, A. Mixed Ab initio QM/MM modeling using frozen orbitais and tests with alanine dipeptide and tetrapeptide. J. Comput. Chem. 1999, 20 (14), 1468-1494.
34. Murphy, R. B.; Philipp, D. M.; Friesner, R. A. A mixed quantum mechanics/molecular mechanics (QM/MM) method for large-scale modeling of chemistry in protein environments. J. Comput. Chem. 2000, 21 (16), 1442-1457.
35. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267 (3), 727-748.
36. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245 (1), 43-53.
37. Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J, F.; Matthew, J. B. Consensus scoring for ligand/protein interactions. J. Mol. Graphics Modell. 2002, 20 (4), 281-295.
38. PyMOL Home Page. http://pymol.sourceforge.net/ (accessed Feb 2008).
39. Bairoch, A.; Apweiler, R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res. 1997, 25 (1), 31-36.
40. Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W,; Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 1990, 215 (3), 403-410.
41. Gabelli, S. B.; McLellan, J. S.; Montalvetti, A.; Oldfield, E.; Docampo, R.; Amzel, L. M. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins 2006, 62 (1), 80-88.
42. Mao, J.; Mukherjee, S.; Zhang, Y.; Cao, R.; Sanders, J. M.; Song, Y.; Zhang, Y.; Meints, G. A.; Gao, Y. G.; Mukkamala, D.; Hudock, M. P.; Oldfield, E. Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthasebisphosphonate complexes. J. Am. Chem. Soc. 2006, 128 (45), 14485-14497.
43. Rondeau, J. M.; Bitsch, F.; Bourgier, E.; Geiser, M.; Hemmig, R.; Kroemer, M.; Lehmann, S.; Ramage, P.; Rieffel, S.; Strauss, A.; Green. J. R.; Jahnke, W. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006, 1 (2), 267-273.
44. Tarshis, L. C.; Yan, M.; Poulter, C. D.; Sacchettini, J. C. Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-A resolution. Biochemistry 1994, 33 (36), 10871-10877.
45. Hosfield, D. J.; Zhang, Y.; Dougan, D. R.; Broun, A.; Tari, L. W.; Swanson, R. V.; Finn, J. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J. Biol. Chem. 2004, 279 (10), 8526-8529.
46. Jorgensen, W. L. M.; David, S.; Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J. Am. Chem. Soc. 1996, 118 (45), 11225-11236.
47. Still, W. C. T.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc. 1990, 112 (16), 6127-6129.
48. Li, X.; Jacobson, M. P.; Friesner, R. A. High-resolution prediction of protein helix positions and orientations. Proteins 2004, 55 (2), 368-382.
49. Felts, A. K.; Gallicchio, E.; Wallqvist, A.; Levy, R. M. Distinguishing native conformations of proteins from decoys with an effective free energy estimator based on the OPLS all-atom force field and the Surface Generalized Born solvent model, Proteins 2002, 48 (2), 404-422.
50. Gherman, B. F.; Goldberg, S. D.; Cornish, V. W.; Friesner, R. A. Mixed quantum mechanical/molecular mechanical (QM/MM) study of the deacylation reaction in a penicillin binding protein (PBP) versus in a class C beta-lactamase. J. Am. Chem. Soc. 2004, 126 (24), 7652-7664.
51. Gherman, B. F,; Lippard, S. J.; Friesner, R. A. Substrate hydroxylation in methane monooxygenase: quantitative modeling via mixed quantum mechanics/molecular mechanics techniques. J. Am. Chem. Soc. 2005, 127(3), 1025-1037.
52. Oelschlaeger, P.; Klahn, M.; Beard, W. A.; Wilson, S. H.; Warshel, A. Magnesium-cationic dummy atom molecules enhance representation of DNA polymerase beta in molecular dynamics simulations: improved accuracy in studies of structural features and mutational effects. J. Mol. Biol. 2007, 366 (2), 687-701.
53. Pang, Y. P. Successful molecular dynamics simulation of two zinc complexes bridged by a hydroxide in Phosphodiesterase using the cationic dummy atom method. Proteins 2001, 45 (3), 183-189.
54. Pang, Y. P.; Xu, K.; Yazal, J. E.; Prendergas, F. G. Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach. Protein Sci. 2000, 9(10), 1857-1865.
55. Banks, J. L.; Beard, H. S.; Cao, Y.; Cho, A. E.; Damm, W.; Farid, R.; Felts, A. K.; Halgren, T. A.; Mainz, D. T.; Maple, J. R.; Murphy, R.; Philipp, D. M.; Repasky, M. P.; Zhang, L. Y.; Berne, B. J.; Friesner, R. A.; Gallicchio, E.; Levy, R. M. Integrated Modeling Program, Applied Chemical Theory (IMPACT). J. Comput. Chem. 2005, 26 (16), 1752-1780.
56. Diaz, N.; Suarez, D.; Sordo, T. L. Quantum chemical study on the coordination environment of the catalytic zinc ion in matrix metall-oproteinases. J. Phys. Chem. B 2006, 110 (47), 24222-24230.
57. Guallar, V.; Jacobson, M.; McDermott, A.; Friesner, R. A. Computational modeling of the catalytic reaction in triosephosphate isomerase. J. Mol. Biol. 2004, 337 (1), 227-239.
58. Rravitz, J. Y.; Pecoraro, V. L.; Carlson, H. A. Quantum Mechanics/Molecular Mechanics Calculations of the Vanadium Dependent Chloroperoxidase. J. Chem. theory Comput. 2005, 1 (6), 1265-1274.
59. Cheng, Y.; Zhang, Y.; McCammon, J. A. How does the cAMPdependent protein kinase catalyze the phosphorylation reaction: an ab initio QM/MM study. J. Am. Chem. Soc. 2005, 127 (5), 1553-1562.
60. Lin, P.; Pedersen, L. C.; Batra, V. K.; Beard, W. A.; Wilson, S. H.; Pedersen, L. G. Energy analysis of chemistry for correct insertion by DNA polymerase beta. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (36), 13294-13299.
61. Alberts, I. L.; Wang, Y.; Schlick, T. DNA polymerase beta catalysis: are different mechanisms possible. J. Am. Chem. Soc. 2007, 129 (36), 11100-11110.
62. Wang, L.; Yu, X.; Hu, P.; Broyde, S.; Zhang, Y. A water-mediated and substrate-assisted catalytic mechanism for Sulfolobus solfataricus DNA polymerase IV. J. Am. Chem. Soc. 2007, 129 (15), 4731-4737.
63. Table 1 Metal Phosphate Interactions in Metalloproteins, http://tanna.bch.ed.ac.uk/mphos/mphos3wt.htm (accessed Feb 2008).
64. Harding, M. M. Small revisions to predicted distances around metal sites in proteins. Acta Crystallogr., Sect. D 2006, 62 (Pt 6), 678-682.
65. Joly, A.; Edwards, P. A. Effect of site-directed mutagenesis of conserved aspartate and arginine residues upon farnesyl diphosphate synthase activity. J. Biol. Chem. 1993, 268 (36), 26983-26989.
66. Song, L.; Poulter, C. D. Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II. Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (8), 3044-3048.
67. Tarshis, L. C.; Proteau, P. J.; Rellogg, B. A.; Sacchettini, J. C.; Poulter, C. D. Regulation of product chain length by isoprenyl diphosphate synthases. Proc. Natl. Acad. Sci. U.S.A. 1996, 93 (26), 15018-15023.
68. Sanders, J. M.; Gomez, A. O.; Mao, J.; Meints, G. A.; Van Brussel, E. M.; Burzynska, A.; Rafarski, P.; Gonzalez-Pacanowska, D.; Oldfield, E. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J. Med. Chem. 2003, 46 (24), 5171-5183.
69. Gold Performance as a Function of Protein Type. http://www.ccdc.cam.ac. uk/support/documentation/gold/3_2/doc/portable_html/gold_portable-3-214.html (accessed Feb 2008).
70. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006, 49 (20), 5912-5931.
71. Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 1999, 42 (5), 791-804.
72. Ha, S.; Andreani, R.; Robbins, A.; Muegge, I. Evaluation of docking/scoring approaches: a comparative study based on MMP3 inhibitors. J. Comput.-Aided Mol. Des. 2000, 14 (5), 435-448.
73. Muegge, I.; Martin, Y. C.; Hajduk, P. J.; Fesik, S. W. Evaluation of PMF scoring in docking weak ligands to the FR506 binding protein. J. Med. Chem. 1999, 42 (14), 2498-2503.